Codis Expands UK Spray Drying Capacity with GEA PSD4 Investment

New commercial-scale solvent spray dryer will enable Codis to meet rising demand for amorphous solid dispersions manufacturing.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying and amorphous solid dispersions (ASDs), announced a major expansion of its UK manufacturing capabilities with the purchase of a GEA Pharma-SD® type PSD-4 solvent-capable spray dryer. This investment, supported by the UK government's Life Sciences Innovative Manufacturing Fund (LSIMF), will make Codis the only UK CDMO offering this large-scale commercial spray drying capacity.

Why it matters

The new PSD4 spray dryer will significantly expand Codis' ASD production capacity, enabling its customers to bring more bioavailability-enhanced medicines to market. This investment strengthens the UK's domestic life sciences manufacturing capabilities and supports local economic development in the Haverhill region.

The details

The PSD4 is a large-scale, cGMP pharmaceutical spray dryer designed to produce commercial batches up to 500 kg with a total capacity of 30,000 kg per year. This expansion responds to rapidly increasing demand for solvent‑based spray drying of ASDs, a proven technology to enhance bioavailability of poorly soluble drug candidates. The new PSD4 complements Codis' existing spray drying platform, which includes a PSD2 unit supporting pilot‑scale and smaller commercial‑scale production.

  • Codis announced the investment on March 4, 2026.
  • The new PSD4 facility will be operational in 2027.

The players

Codis

A global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering.

GEA

A manufacturer of the Pharma-SD® type PSD-4 solvent-capable spray dryer that Codis is investing in.

UK government

Provided support for Codis' investment through the Life Sciences Innovative Manufacturing Fund (LSIMF), which offers capital grants to life science manufacturers.

Got photos? Submit your photos here. ›

What they’re saying

“This milestone marks the next phase in Codis' evolution as a global leader in spray drying and ASD. The PSD4 significantly expands our ASD capacity and gives customers dedicated commercial‑scale throughput to bring more life‑changing medicines to market. We are grateful for the support of the UK government through the LSIMF, which enables us to accelerate this project and continue investing at our Haverhill site.”

— Nicolas Fortin, Chief Executive Officer of Codis (PRNewswire)

What’s next

Construction, installation, and commissioning of the PSD4 will create short‑term employment opportunities in the Haverhill region, with additional long‑term roles expected as production ramps up.

The takeaway

Codis' investment in a new commercial-scale solvent spray dryer at its UK facility strengthens the country's domestic life sciences manufacturing capabilities and supports local economic development, while also enabling the company to better meet rising demand for amorphous solid dispersions to enhance the bioavailability of new drug candidates.